97290 ⎘
Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components Diabody or triabody
IMMUNOTOXIN FOR CANCER IMMUNOTHERAPY
#2MULTIVALENT FZD4, WNT CO-RECEPTOR, AND VEGF BINDING MOLECULES AND USES THEREOF
#3MULTIVALENT FZD4, WNT CO-RECEPTOR, AND VEGF RECEPTOR MOLECULES AND USES THEREOF
#4MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
#5METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASE
#6ISOLATED ANTIGEN BINDING PROTEIN AND USE THEREOF
#7METHODS AND COMPOSITIONS REGARDING CYCLIC PEPTIDES FOR USE WITH ANTIBODIES AND ANTIBODY FRAGMENTS
#8Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
#9ANTIBODIES SPECIFICALLY RECOGNIZING PROGRAMMED CELL DEATH1 LIGAND 1 AND USES THEREOF
#10ANTIGEN BINDING CONSTRUCTS TO CD8
#11Binding Proteins 1
#12IMPROVED DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#13ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES
#14BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
#15ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF
#16METHODS AND COMPOSITIONS FOR TREATING BARTH SYNDROME
#17COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOF
#18Antibodies to Amyloid Beta
#19CTLA4-BINDING PROTEINS AND METHODS OF TREATING CANCER
#20METHODS OF TREATING INFLAMMATION
#21ANTIBODIES AND METHODS OF MAKING AND USING SAME
#22Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof
#23ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY
#24ANTIGEN BINDING PROTEINS CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN
#25METHOD FOR THE PRODUCTION OF DOMAIN ANTIBODIES
#26Anti-Polyubiquitin Multispecific Antibodies
#27ADAM9-Binding Molecules, and Methods of Use Thereof
#28TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#29BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#30MANABODIES TARGETING P53 TUMOR ANTIGENS AND METHODS OF USING
#31Anti-thyroglobulin Antibody, Kit and Use Thereof
#32METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASE
#33ANTI-HUMAN CD10 ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS TO DIAGNOSE CANCER
#34BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#35PILRA ANTIBODIES AND METHODS OF USE THEREOF
#36APPARATUS AND METHOD FOR OOCYTE RESCUE IN VITRO POST STIMULATION
#37THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1
#38SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
#39COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES
#40ANTI-CD3 ANTIBODIES
#41BISPECIFIC ANTIBODY AND USE THEREOF
#42SERUM ALBUMIN BINDERS
#43MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
#44COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES
#45NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF
#46ANTI-FIBROBLAST ACTIVATION PROTEIN ANTIBODIES
#47MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#48METHODS AND MATERIALS FOR TREATING CLONAL T CELL EXPANSIONS
#49LAG-3-Binding Molecules and Methods of Use Thereof
#50TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#51ANTIBODIES TO TICAGRELOR AND METHODS OF USE
#52TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#53METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4
#54VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF
#55POLYPEPTIDES FOR DETECTION AND TREATMENT OF SARS-COV-2
#56Antibody Constructs for CDH19 and CD3
#57Bispecific antibody binding BCMA and CD3
#58Binding proteins 1
#59METHODS FOR CONCENTRATING PROTEINS
#60NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#61IMPROVED DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#62BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#63METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE
#64DOSAGE UNITS AND REGIMEN, USES, METHODS OR FORMULATIONS OF COMPOSITIONS COMPRISING A RECOMBINANT PROTEIN COMPRISING INTERLEUKIN-12 AND AN ANTIBODY BINDING THE EXTRA-DOMAIN B OF FIBRONECTIN
#65TGF-β3 specific antibodies and methods and uses thereof
#66Anti-TNF-alpha-antibodies and functional fragments thereof
#67Anti-TNF-alpha-antibodies and functional fragments thereof
#68CYTOKINE VARIANT ANTIBODIES AND METHODS OF USE
#69Anti-transferrin receptor antibodies with tailored affinity
#70RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE
#71TCR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING
#72METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF
#73Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
#74Cleavable tetrazine used in bio-orthogonal drug activation
#75Tetravalent FZD and WNT Co-receptor Binding Molecules and Uses Thereof
#76SPLIT CH2 DOMAINS
#77Pre-diffuser for a gas turbine engine
#78TRISPECIFIC ANTIBODIES
#79NOVEL ANTI-CD3 ANTIBODIES
#80TRIVALENT BINDING MOLECULES
#81Methods and compositions for reducing the immunogenicity of chimeric notch receptors
#82scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
#83METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
#84ALK7 BINDING PROTEINS AND USES THEREOF
#85BISPECIFIC PROTEIN
#86Hetero-dimeric multi-specific antibody format
#87ADAM9-Binding Molecules, and Methods of Use Thereof
#88NOVEL MOLECULAR TOOLS TO VISUALIZE AND TARGET THE CARDIAC CONDUCTION SYSTEM (CCS)
#89Multivalent FZD and WNT Binding Molecules and Uses Thereof
#90SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS
#91ANTIBODIES AND BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER
#92Covalent Diabodies and Uses Thereof
#93ENGINEERED T-CELLS CO-EXPRESSING AN ANTI-BCMA CAR AND AN ANTI-ECTOENZYME ANTIBODY AND THEIR USE IN THE TREATMENT OF CANCER
#94Anti-polyubiquitin multispecific antibodies
#95RANK ANTAGONISTS AND USES THEREOF
#96TRIPLE-CHAIN ANTIBODY, METHOD FOR PREPARATION AND USE THEREOF
#97Anti-BAG3 antibodies as therapeutic reagent in cardiovascular disease
#98ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN
#99DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#100DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#101Bispecific HER2 Ligands for Cancer Therapy
#102Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
#103TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#104Anti-PD-L1 diabodies and the use thereof
#105Human IL-23 antigen binding proteins
#106METHODS FOR TREATING PANCREATITIS
#107METHODS OF TREATING INFLAMMATION
#108TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE
#109Tandem diabody for CD16A-directed NK-cell engagement
#110Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use Thereof
#111Neutralizing anti-influenza A antibodies and uses thereof
#112BISPECIFIC ANTIBODY BINDING TO CD20 AND CD3 AND USES THEREOF
#113Antibodies to ticagrelor and methods of use
#114ANTIGEN BINDING CONSTRUCTS TO CD4
#115IL2 AND TNF MUTANT IMMUNOCONJUGATES
#116METHODS AND COMPOSITIONS FOR TREATING TAUOPATHIES
#117RETINAL GANGLION CELL DEATH INHIBITOR
#118COMPOSITIONS AND METHODS FOR ENHANCING DONOR OLIGONUCLEOTIDE-BASED GENE EDITING
#119Stabilized antibody compositions
#120Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders
#121METHOD OF TREATING CANCER
#122Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#123Epitope specific antibodies that bind cell surface GRP78 and their use for cancer detection
#124Anti-TrkB agonist antibodies binding to D1 domain of TrkB
#125BISPECIFIC AFFINITY REAGENT AND RELATED METHODS FOR PRETARGETED RADIOIMMUNOTHERAPY AGAINST CD45+ CELL
#126METHOD OF TREATING WASTING DISORDERS
#127Method of Generating Anti-Linaclotide Antibodies and Uses Thereof
#128Optimized gp41-Binding Molecules and Uses Thereof
#129LAG-3-binding molecules and methods of use thereof
#130Anti-TNF-alpha-antibodies and functional fragments thereof
#131Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#132Bispecific CD16-binding molecules and their use in the treatment of disease
#133Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
#134Variant CD3-binding domains and their use in combination therapies for the treatment of disease
#135Mono and bispecific antibody binding to hERG1 and hERG1/integrin beta 1
#136SPNS2 neutralizing antibody
#137Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
#138Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
#139Mosaic chimeric viral vaccine particle
#140Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#141Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#142Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
#143Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
#144Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof
#145Compositions comprising cyclic peptides derived from an A-beta peptide
#146RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE
#147Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
#148Methods of using bispecific CD33 and CD3 binding proteins
#149Bispecific CD33 and CD3 Binding Proteins
#150Nucleic acids encoding anti-CD40 antibodies
#151Therapeutic molecules that bind to LAG3 and PD1
#152METHODS AND REAGENTS FOR REDUCING THE INTERFERENCE OF DRUGS THAT BIND CD47 IN SEROLOGICAL ASSAYS
#153TGF-β3 specific antibodies and methods and uses thereof
#154Methods for treating hematologic cancers
#155Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
#156Bispecific molecules comprising an HIV-1 envelope targeting arm
#157Compositions and methods for targeting CLEC12A-expressing cancers
#158Anti-CD83 antibodies and use thereof
#159Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
#160Anti-AXL tyrosine kinase receptor antibodies and uses thereof
#161BISPECIFIC ANTIBODY
#162Methods and compositions for engineering immunity
#163BINDING AGENT
#164TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#165COMBINATION THERAPY
#166NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#167Binding proteins 1
#168Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
#169Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
#170HER3 binding agents and uses thereof
#171Multi-chain polypeptide-containing tri-specific binding molecules
#172MULTIVALENT FRAGMENTS OF ANTIBODY 3E10 AND METHODS OF USE THEREOF
#173Tri-specific binding molecules that specifically bind to multiple cancer antigens
#174Anti-GARP protein
#175Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
#176Human IL-23 Antigen Binding Proteins
#177Humanized antibodies binding to amyloid-beta (A-beta)
#178Attenuated porcine sapelovirus strain and immunogenic compositions therefrom
#179IMMUNOCONJUGATES WITH OPTIMIZED LINKERS AND ORIENTATION
#180Method of Generating Anti-Linaclotide Antibodies and Uses Thereof
#181ANTIGEN BINDING CONSTRUCTS TO CD8
#182Antibodies that bind cell surface GRP78
#183Light chain variable regions
#184scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
#185Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
#186Anti-CD3 antibodies
#187Neutralizing anti-influenza A antibodies and uses thereof
#188Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
#189Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#190CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#191Method of screening for anti-GARP antibodies
#192Mosaic chimeric viral vaccine particle
#193Method for the treatment or prevention of a disease related to vascular endothelial lipase by administering a humanized monoclonal antibody
#194Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
#195IL2 and TNF mutant immunoconjugates
#196Anti-transferrin receptor antibodies with tailored affinity
#197Antigen binding molecules and methods of use thereof
#198STABLE MULTIPLE ANTIGEN-BINDING ANTIBODY
#199Treatment of cancer with anti-LAP monoclonal antibodies
#200Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma
#201Combination of an anti-CD16A antibody with a cytokine
#202Thrombin-binding antibody molecules and uses thereof
#203ADAM9-binding molecules, and methods of use thereof
#204ANTIGEN BINDING CONSTRUCTS TO CD8
#205Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
#206TRISPECIFIC ANTIBODIES
#207Tandem diabody for CD16A-directed NK-cell engagement
#208Folate receptor 1 antibodies and immunoconjugates and uses thereof
#209ANTI-GUANOSINE ANTIBODY AS A MOLECULAR DELIVERY VEHICLE
#210Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and Disorders
#211HUMAN IL-23 ANTIGEN BINDING PROTEINS
#212Antibodies to olanzapine and use thereof
#213Antigen binding constructs to CD3
#214STABILIZED ANTIBODY COMPOSITIONS
#215Cleavable tetrazine used in bio-orthogonal drug activation
#216Antigen binding protein against HER3
#217Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
#218Anti-TNF-alpha-antibodies and functional fragments thereof
#219Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
#220Anti-polyubiquitin multispecific antibodies
#221IL22 immunoconjugates
#222Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
#223Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
#224Anti-TNFα-antibodies and functional fragments thereof
#225Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#226Covalent diabodies and uses thereof
#227Covalent Diabodies and Uses Thereof
#228Anti-TNFα-antibodies and functional fragments thereof
#229Anti-CD40 antibodies
#230LAG-3-binding molecules and methods of use thereof
#231Antibodies to ticagrelor and methods of use
#232ANTI-EMP2 THERAPY REDUCES CANCER STEM CELLS
#233Human IL-23 Antigen Binding Proteins
#234GM hybridoma cell, monoclonal antibody, kit and preparation method and use thereof
#235PcrV binding single variable domain antibodies
#236DLL3 MODULATORS AND METHODS OF USE
#237Multivalent FV antibodies
#238METHOD OF TREATING CANCER
#239Antibody against a complex between human GARP and latent TGF-β
#240Antibody constructs for CDH19 and CD3
#241DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#242DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#243DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#244Dual specificity polypeptide molecule
#245Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
#246Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#247Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
#248ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF
#249ANTI-NGF ANTIBODIES AND THEIR USE
#250Methods and compositions for reducing the immunogenicity of chimeric notch receptors
#251Hetero-dimeric multi-specific antibody format
#252ANTIGEN-BINDING MOLECULE AND USES THEREOF
#253Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#254Thrombin-binding antibody molecules and uses thereof
#255Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#256Bispecific CD33 and CD3 binding proteins
#257Bispecific Constructs and Their Use in the Treatment of Various Diseases
#258Anti-transferrin receptor antibodies with tailored affinity
#259BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#260Bispecific antibody binding TRAIL-R2 and CD3
#261Antibodies and assays for detection of CD37
#262Novel Treatment Methods Based on Multifunctional Molecules
#263ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
#264Extension sequences for diabodies
#265Anti-OX40 antibodies and diagnostic uses thereof
#266Anti-CD83 antibodies and use thereof
#267Covalent diabodies and uses thereof
#268BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
#269Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#270COVALENT DISULFIDE-LINKED DIABODIES AND USES THEREOF
#271Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#272Methods of using bispecific CD33 and CD3 binding proteins
#273TGF-β3 specific antibodies and methods and uses thereof
#274Bispecific molecules comprising an HIV-1 envelope targeting arm
#275Antibody dual display dual compositions and methods of use thereof
#276Material and methods for treating or preventing HER-3 associated diseases
#277Antibodies reactive with B7-H3 and users thereof
#278Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
#279RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
#280Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
#281RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
#282Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
#283Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
#284ANTIBODIES THAT BIND CELL SURFACE GRP78 AND THEIR USE FOR DETECTION OF CANCER
#285AMYLOID-BETA BINDING PROTEINS
#286Mosaic chimeric viral vaccine particle
#287Antibodies that bind to CCR6 and their uses
#288Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
#289Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
#290Anti-ED-A immunoconjugates for inflammatory bowel disease
#291Methods of delivering DLL3 antibody drug conjugates
#292Methods of making DLL3 antibody drug conjugates
#293Treatment of cancer with anti-lap monoclonal antibodies
#294Chimeric antigen receptors with an optimized hinge region
#295Antigen binding molecules and methods of use thereof
#296ANTI-TAU CONSTRUCTS
#297Anti-DLL3 antibody drug conjugates and methods of use
#298Treatment of cancer with anti-LAP monoclonal antibodies
#299PREDICTIVE MARKER FOR TOPOISOMERASE I INHIBITORS
#300Anti-DLL3 antibody drug conjugates